Biotech · Private company · Dover, DE, US
Lomond Therapeutics Holdings, Inc.
SEC CIK 0001900520
Track this companyFree. Adds Lomond Therapeutics Holdings, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials22 recruiting or active
Pipeline programs2From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline2
- Lonitoclax (ZE50-0134)Phase 1 · CLL / SLLClinicalTrials.gov · fetched Nov 12, 2026
- ZE46-0134Phase 1 · AML With Gene MutationsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell MalignanciesPHASE1 · RECRUITING · started Apr 8, 2025ClinicalTrials.gov NCT06708897 · fetched Nov 12, 2026
- Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid LeukemiaPHASE1 · RECRUITING · started May 29, 2024ClinicalTrials.gov NCT06366789 · fetched Nov 12, 2026
SEC filings12
- 10-Q · QUARTERLY REPORTSEC EDGAR · filed May 15, 2026 · fetched Nov 12, 2026
- 10-K · ANNUAL REPORTSEC EDGAR · filed Apr 15, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jan 13, 2026 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jan 13, 2026 · fetched Nov 12, 2026
- 10-Q · QUARTERLY REPORTSEC EDGAR · filed Nov 14, 2025 · fetched Nov 12, 2026
- 10-Q · QUARTERLY REPORTSEC EDGAR · filed Aug 14, 2025 · fetched Nov 12, 2026
- S-1/A · AMENDMENT NO. 4 TO FORM S-1SEC EDGAR · filed Aug 1, 2025 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Jun 20, 2025 · fetched Nov 12, 2026
- S-1/A · AMENDMENT NO. 3 TO FORM S-1SEC EDGAR · filed Jun 18, 2025 · fetched Nov 12, 2026
- 10-Q · QUARTERLY REPORTSEC EDGAR · filed May 20, 2025 · fetched Nov 12, 2026
- 10-K · ANNUAL REPORTSEC EDGAR · filed Apr 15, 2025 · fetched Nov 12, 2026
- 8-K · CURRENT REPORTSEC EDGAR · filed Mar 28, 2025 · fetched Nov 12, 2026